Pathophysiological aspects of transferrin-A potential nano-based drug delivery signaling molecule in therapeutic target for varied diseases

Transferrin (Tf), widely known for its role as an iron-binding protein, exemplifies multitasking in biological processes. The role of Tf in iron metabolism involves both the uptake of iron from Tf by various cells, as well as the endocytosis mediated by the complex of Tf and the transferrin receptor (TfR). The direct conjugation of the therapeutic compound and immunotoxin studies using Tf peptide or anti-Tf receptor antibodies as targeting moieties aims to prolong drug circulation time and augment efficient cellular drug uptake, diminish systemic toxicity, traverse the blood-brain barrier, restrict systemic exposure, overcome multidrug resistance, and enhance therapeutic efficacy with disease specificity. This review primarily discusses the various biological actions of Tf, as well as the development of Tf-targeted nano-based drug delivery systems. The goal is to establish the use of Tf as a disease-targeting component, accentuating the potential therapeutic applications of this protein.

[1]  Yi Wang,et al.  The blood–brain barrier: Structure, regulation and drug delivery , 2023, Signal transduction and targeted therapy.

[2]  A. Yusuf,et al.  Nanoparticles as Drug Delivery Systems: A Review of the Implication of Nanoparticles’ Physicochemical Properties on Responses in Biological Systems , 2023, Polymers.

[3]  Xiyun Yan,et al.  Transferrin receptor 1 targeted nanomedicine for brain tumor therapy. , 2023, Biomaterials science.

[4]  I. Boldyrev,et al.  Intranasal Delivery of Liposomes to Glioblastoma by Photostimulation of the Lymphatic System , 2022, Pharmaceutics.

[5]  Alexander S. Timin,et al.  Overcoming the blood–brain barrier for the therapy of malignant brain tumor: current status and prospects of drug delivery approaches , 2022, Journal of Nanobiotechnology.

[6]  S. Mousa,et al.  Intranasal delivery in glioblastoma treatment: prospective molecular treatment modalities , 2022, Heliyon.

[7]  Wanqing Chen,et al.  Cancer statistics in China and United States, 2022: profiles, trends, and determinants , 2022, Chinese medical journal.

[8]  M. Coelho,et al.  Transferrin Receptor-Targeted Nanocarriers: Overcoming Barriers to Treat Glioblastoma , 2022, Pharmaceutics.

[9]  C. Riccardi,et al.  Nanoparticle-Guided Brain Drug Delivery: Expanding the Therapeutic Approach to Neurodegenerative Diseases , 2021, Pharmaceutics.

[10]  Ludan Zhao,et al.  A pH-sensitive T7 peptide-decorated liposome system for HER2 inhibitor extracellular delivery: an application for the efficient suppression of HER2+ breast cancer. , 2021, Journal of materials chemistry. B.

[11]  G. Husseini,et al.  Transferrin-modified liposomes triggered with ultrasound to treat HeLa cells , 2021, Scientific Reports.

[12]  Xiaolu Liu,et al.  Baicalein inhibits RLS3-induced ferroptosis in melanocytes. , 2021, Biochemical and biophysical research communications.

[13]  Y. Kuo,et al.  Multiple-component dual-phase solid lipid nanoparticles with conjugated transferrin for formulating antioxidants and nerve growth factor against neuronal apoptosis , 2020 .

[14]  Steven J. P. McInnes,et al.  Active targeting towards and inside the brain based on nanoparticles: A Review. , 2019, Current pharmaceutical biotechnology.

[15]  Shubiao Zhang,et al.  Targeting Strategies for SuperParamagnetic Iron Oxide Nanoparticles in Cancer Therapy. , 2019, Acta biomaterialia.

[16]  Qiongxiu Zhou,et al.  Mitochondria as a therapeutic target for ischemic stroke. , 2019, Free radical biology & medicine.

[17]  Chengwen Sun,et al.  Dual functionalized liposomes for efficient co-delivery of anti-cancer chemotherapeutics for the treatment of glioblastoma. , 2019, Journal of controlled release : official journal of the Controlled Release Society.

[18]  M. Memo,et al.  DMT1 Expression and Iron Levels at the Crossroads Between Aging and Neurodegeneration , 2019, Front. Neurosci..

[19]  A. Grumezescu,et al.  Nanomaterials for Drug Delivery to the Central Nervous System , 2019, Nanomaterials.

[20]  Qian Zhang,et al.  Transferrin-functionalised microemulsion co-delivery of β-elemene and celastrol for enhanced anti-lung cancer treatment and reduced systemic toxicity , 2019, Drug Delivery and Translational Research.

[21]  M. Weller,et al.  Chemotherapy sensitization of glioblastoma by focused ultrasound‐mediated delivery of therapeutic liposomes , 2019, Journal of controlled release : official journal of the Controlled Release Society.

[22]  J. Tsai,et al.  A Rational Approach for Creating Peptides Mimicking Antibody Binding , 2019, Scientific Reports.

[23]  Sushant Lakkadwala,et al.  Co-delivery of doxorubicin and erlotinib through liposomal nanoparticles for glioblastoma tumor regression using an in vitro brain tumor model. , 2019, Colloids and surfaces. B, Biointerfaces.

[24]  Yang Yang,et al.  Dual-Modified Novel Biomimetic Nanocarriers Improve Targeting and Therapeutic Efficacy in Glioma. , 2018, ACS applied materials & interfaces.

[25]  Shu-ling Wang,et al.  Drug delivery systems for elemene, its main active ingredient β-elemene, and its derivatives in cancer therapy , 2018, International journal of nanomedicine.

[26]  J. Jankovic,et al.  Safety and Tolerability of Multiple Ascending Doses of PRX002/RG7935, an Anti–&agr;-Synuclein Monoclonal Antibody, in Patients With Parkinson Disease: A Randomized Clinical Trial , 2018, JAMA neurology.

[27]  V. Torchilin,et al.  Transferrin‐targeted, resveratrol‐loaded liposomes for the treatment of glioblastoma , 2018, Journal of controlled release : official journal of the Controlled Release Society.

[28]  M. Andjelkovic,et al.  A phase III randomized trial of gantenerumab in prodromal Alzheimer’s disease , 2017, Alzheimer's Research & Therapy.

[29]  G. Cairo,et al.  The transferrin receptor: the cellular iron gate. , 2017, Metallomics : integrated biometal science.

[30]  B. Stockwell,et al.  Ferroptosis: A Regulated Cell Death Nexus Linking Metabolism, Redox Biology, and Disease , 2017, Cell.

[31]  Feng Xu,et al.  Recent advances of controlled drug delivery using microfluidic platforms☆ , 2017, Advanced drug delivery reviews.

[32]  O. Nedić,et al.  A microscale protocol for the isolation of transferrin directly from serum. , 2017, Clinica chimica acta; international journal of clinical chemistry.

[33]  A. Atilgan,et al.  Mechanisms by Which Salt Concentration Moderates the Dynamics of Human Serum Transferrin. , 2017, The journal of physical chemistry. B.

[34]  Zhenzhong Zhang,et al.  Copper sulfide nanoparticle-based localized drug delivery system as an effective cancer synergistic treatment and theranostic platform. , 2017, Acta biomaterialia.

[35]  S. Rivella,et al.  A Red Carpet for Iron Metabolism , 2017, Cell.

[36]  Gang Chen,et al.  Ferroptosis, a new form of cell death, and its relationships with tumourous diseases , 2016, Journal of cellular and molecular medicine.

[37]  D. B. Vieira,et al.  Getting into the brain: liposome-based strategies for effective drug delivery across the blood–brain barrier , 2016, International journal of nanomedicine.

[38]  Zhixing Zheng,et al.  T7 Peptide-Functionalized PEG-PLGA Micelles Loaded with Carmustine for Targeting Therapy of Glioma. , 2016, ACS applied materials & interfaces.

[39]  K. Rhodes,et al.  The antibody aducanumab reduces Aβ plaques in Alzheimer’s disease , 2016, Nature.

[40]  Jiancheng Wang,et al.  Brain tumor-targeted therapy by systemic delivery of siRNA with Transferrin receptor-mediated core-shell nanoparticles. , 2016, International journal of pharmaceutics.

[41]  Hyun-soo Cho,et al.  Endosomal acidic pH-induced conformational changes of a cytosol-penetrating antibody mediate endosomal escape. , 2016, Journal of controlled release : official journal of the Controlled Release Society.

[42]  M. Penichet,et al.  Transferrin receptor 1: a target for antibody-mediated cancer therapy. , 2016, Immunotherapy.

[43]  Chen Jiang,et al.  Dual Functional Peptide-Driven Nanoparticles for Highly Efficient Glioma-Targeting and Drug Codelivery. , 2016, Molecular pharmaceutics.

[44]  L. Lannfelt,et al.  Safety and tolerability of BAN2401 - a clinical study in Alzheimer’s disease with a protofibril selective Aβ antibody , 2016, Alzheimer's Research & Therapy.

[45]  Min‐Geol Lee,et al.  Oxidative stress and antioxidant strategies in dermatology , 2016, Redox report : communications in free radical research.

[46]  V. Ceña,et al.  Nanoparticles for brain-specific drug and genetic material delivery, imaging and diagnosis. , 2016, Nanomedicine.

[47]  G. Antoni,et al.  Antibody-based PET imaging of amyloid beta in mouse models of Alzheimer's disease , 2016, Nature Communications.

[48]  Ying-zheng Zhao,et al.  Brain tumor-targeted delivery and therapy by focused ultrasound introduced doxorubicin-loaded cationic liposomes , 2016, Cancer Chemotherapy and Pharmacology.

[49]  T. Moos,et al.  Revisiting nanoparticle technology for blood-brain barrier transport: Unfolding at the endothelial gate improves the fate of transferrin receptor-targeted liposomes. , 2016, Journal of controlled release : official journal of the Controlled Release Society.

[50]  P. Vandenabeele,et al.  Regulated necrosis: disease relevance and therapeutic opportunities , 2016, Nature Reviews Drug Discovery.

[51]  B. Spellberg,et al.  Transferrin-mediated iron sequestration as a novel therapy for bacterial and fungal infections. , 2015, Current opinion in microbiology.

[52]  Mark E. Davis,et al.  Increased brain uptake of targeted nanoparticles by adding an acid-cleavable linkage between transferrin and the nanoparticle core , 2015, Proceedings of the National Academy of Sciences.

[53]  T. Moos,et al.  Divalent metal transporter 1 (DMT1) in the brain: implications for a role in iron transport at the blood-brain barrier, and neuronal and glial pathology , 2015, Front. Mol. Neurosci..

[54]  Atsushi B. Tsuji,et al.  Evaluation of Efficacy of Radioimmunotherapy with 90Y-Labeled Fully Human Anti-Transferrin Receptor Monoclonal Antibody in Pancreatic Cancer Mouse Models , 2015, PloS one.

[55]  T. Garg,et al.  Current strategies for targeted delivery of bio-active drug molecules in the treatment of brain tumor , 2015, Journal of drug targeting.

[56]  M. Ghosh,et al.  Blood Brain Barrier: A Challenge for Effectual Therapy of Brain Tumors , 2015, BioMed research international.

[57]  P. Arosio,et al.  The importance of iron in pathophysiologic conditions , 2015, Front. Pharmacol..

[58]  I. Ahmed,et al.  Development of microspheres for biomedical applications: a review , 2014, Progress in Biomaterials.

[59]  Eric P. Skaar,et al.  Transferrin iron starvation therapy for lethal bacterial and fungal infections. , 2014, The Journal of infectious diseases.

[60]  P. Freskgård,et al.  A Human Blood-Brain Barrier Transcytosis Assay Reveals Antibody Transcytosis Influenced by pH-Dependent Receptor Binding , 2014, PloS one.

[61]  T. Rouault,et al.  The physiological functions of iron regulatory proteins in iron homeostasis - an update , 2014, Front. Pharmacol..

[62]  J. Robert,et al.  Transferrin as a drug carrier: Cytotoxicity, cellular uptake and transport kinetics of doxorubicin transferrin conjugate in the human leukemia cells. , 2014, Toxicology in vitro : an international journal published in association with BIBRA.

[63]  Qiang Zhang,et al.  Core-shell type lipid/rPAA-Chol polymer hybrid nanoparticles for in vivo siRNA delivery. , 2014, Biomaterials.

[64]  Nick C Fox,et al.  Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease. , 2014, The New England journal of medicine.

[65]  E. Siemers,et al.  Phase 3 trials of solanezumab for mild-to-moderate Alzheimer's disease. , 2014, The New England journal of medicine.

[66]  P. Oliveira,et al.  Doxorubicin‐Induced Cardiotoxicity: From Bioenergetic Failure and Cell Death to Cardiomyopathy , 2014, Medicinal research reviews.

[67]  Seong-Cheol Park,et al.  Encapsulation of paclitaxel into lauric acid-O-carboxymethyl chitosan-transferrin micelles for hydrophobic drug delivery and site-specific targeted delivery. , 2013, International journal of pharmaceutics.

[68]  Chi-Hwa Wang,et al.  Transferrin-conjugated magnetic silica PLGA nanoparticles loaded with doxorubicin and paclitaxel for brain glioma treatment. , 2013, Biomaterials.

[69]  Zhijun Jia,et al.  Transferrin modified PEG-PLA-resveratrol conjugates: in vitro and in vivo studies for glioma. , 2013, European journal of pharmacology.

[70]  Q. Lan,et al.  Transferrin-modified Doxorubicin-loaded biodegradable nanoparticles exhibit enhanced efficacy in treating brain glioma-bearing rats. , 2013, Cancer biotherapy & radiopharmaceuticals.

[71]  G. Barratt Targeted drug delivery. Editorial. , 2013, International journal of pharmaceutics.

[72]  Chen Jiang,et al.  T7 peptide-functionalized nanoparticles utilizing RNA interference for glioma dual targeting. , 2013, International journal of pharmaceutics.

[73]  Q. Lan,et al.  Transferrin modified graphene oxide for glioma-targeted drug delivery: in vitro and in vivo evaluations. , 2013, ACS applied materials & interfaces.

[74]  Yu-Lan Hu,et al.  Glioma targeting and blood-brain barrier penetration by dual-targeting doxorubincin liposomes. , 2013, Biomaterials.

[75]  H. Ackermann,et al.  Transferrin-Coated Gadolinium Nanoparticles as MRI Contrast Agent , 2013, Molecular Imaging and Biology.

[76]  M. Pellegrini,et al.  Insights into the mechanism of cell death induced by saporin delivered into cancer cells by an antibody fusion protein targeting the transferrin receptor 1. , 2013, Toxicology in vitro : an international journal published in association with BIBRA.

[77]  Xuwei Chen,et al.  Quantum dots conjugated with Fe3O4-filled carbon nanotubes for cancer-targeted imaging and magnetically guided drug delivery. , 2012, Langmuir : the ACS journal of surfaces and colloids.

[78]  S. Rocha,et al.  TfR1 interacts with the IKK complex and is involved in IKK–NF-κB signalling , 2012, The Biochemical journal.

[79]  H. Ackermann,et al.  Contrast Enhancement of the Brain by Folate-Conjugated Gadolinium–Diethylenetriaminepentaacetic Acid–Human Serum Albumin Nanoparticles by Magnetic Resonance Imaging , 2012, Molecular imaging.

[80]  J. Benoit,et al.  Transferrin Adsorption onto PLGA Nanoparticles Governs Their Interaction with Biological Systems from Blood Circulation to Brain Cancer Cells , 2012, Pharmaceutical Research.

[81]  Yan Li,et al.  A dual-targeting nanocarrier based on poly(amidoamine) dendrimers conjugated with transferrin and tamoxifen for treating brain gliomas. , 2012, Biomaterials.

[82]  M. Cogné,et al.  Transglutaminase is essential for IgA nephropathy development acting through IgA receptors , 2012, The Journal of experimental medicine.

[83]  R. MacGillivray,et al.  Structure-based mutagenesis reveals critical residues in the transferrin receptor participating in the mechanism of pH-induced release of iron from human serum transferrin. , 2012, Biochemistry.

[84]  R. Ippoliti,et al.  Distinct cellular responses induced by saporin and a transferrin–saporin conjugate in two different human glioblastoma cell lines , 2012, Journal of cellular physiology.

[85]  K. Pantopoulos,et al.  Regulation of iron transport and the role of transferrin. , 2012, Biochimica et biophysica acta.

[86]  B. Nemesure,et al.  Differential Expression of Transferrin Receptor (TfR) in a Spectrum of Normal to Malignant Breast Tissues: Implications for In Situ and Invasive Carcinoma , 2011, Applied immunohistochemistry & molecular morphology : AIMM.

[87]  J. Barton,et al.  A diagnostic approach to hyperferritinemia with a non-elevated transferrin saturation. , 2011, Journal of hepatology.

[88]  Xin-guo Jiang,et al.  Enhanced intracellular delivery and chemotherapy for glioma rats by transferrin-conjugated biodegradable polymersomes loaded with doxorubicin. , 2011, Bioconjugate chemistry.

[89]  D. Hanahan,et al.  Hallmarks of Cancer: The Next Generation , 2011, Cell.

[90]  Paul C. Wang,et al.  A nanocomplex system as targeted contrast agent delivery vehicle for magnetic resonance imaging dynamic contrast enhancement study. , 2010, Journal of nanoscience and nanotechnology.

[91]  Vincent M Rotello,et al.  The role of surface functionality on acute cytotoxicity, ROS generation and DNA damage by cationic gold nanoparticles. , 2010, Small.

[92]  Chee Wee Gan,et al.  Transferrin-conjugated nanoparticles of poly(lactide)-D-alpha-tocopheryl polyethylene glycol succinate diblock copolymer for targeted drug delivery across the blood-brain barrier. , 2010, Biomaterials.

[93]  M. Rajput,et al.  Microspheres in cancer therapy. , 2010, Indian journal of cancer.

[94]  N. Plesnila,et al.  Tf-lipoplex-mediated c-Jun silencing improves neuronal survival following excitotoxic damage in vivo. , 2010, Journal of controlled release : official journal of the Controlled Release Society.

[95]  R. Murthy,et al.  Paclitaxel-loaded PLGA nanoparticles surface modified with transferrin and Pluronic®P85, an in vitro cell line and in vivo biodistribution studies on rat model , 2009, Journal of drug targeting.

[96]  M. Guo,et al.  Iron-binding and anti-Fenton properties of baicalein and baicalin. , 2009, Journal of inorganic biochemistry.

[97]  J. Sheng,et al.  Growth Inhibition against Intracranial C6 Glioma Cells by Stereotactic Delivery of BCNU by Controlled Release from poly(D,L-lactic acid) Nanoparticles , 2009, Technology in cancer research & treatment.

[98]  T. Daniels,et al.  Conjugation of an anti–transferrin receptor IgG3-avidin fusion protein with biotinylated saporin results in significant enhancement of its cytotoxicity against malignant hematopoietic cells , 2007, Molecular Cancer Therapeutics.

[99]  T. Ganz,et al.  Effects of plasma transfusion on hepcidin production in human congenital hypotransferrinemia , 2007, Haematologica.

[100]  E. Shusta,et al.  Blood–Brain Barrier Transport of Therapeutics via Receptor-Mediation , 2007, Pharmaceutical Research.

[101]  B. Davidson,et al.  Transvascular delivery of small interfering RNA to the central nervous system , 2007, Nature.

[102]  T. Karagiannis,et al.  Receptor-mediated DNA-targeted photoimmunotherapy. , 2006, Cancer research.

[103]  N. Žarković,et al.  Altered iron metabolism, transferrin receptor 1 and ferritin in patients with colon cancer. , 2006, Cancer letters.

[104]  G. Koning,et al.  Radioprotective effect of transferrin targeted citicoline liposomes , 2006, Journal of drug targeting.

[105]  J. Kamps,et al.  Liposome Opsonization , 2005, Journal of liposome research.

[106]  P. Aisen,et al.  Transferrin receptor 1. , 2004, The international journal of biochemistry & cell biology.

[107]  S. Sahoo,et al.  Efficacy of transferrin‐conjugated paclitaxel‐loaded nanoparticles in a murine model of prostate cancer , 2004, International journal of cancer.

[108]  C. Lécureuil,et al.  Transgenic mice as a model to study the regulation of human transferrin expression in Sertoli cells. , 2004, Human reproduction.

[109]  M. Büchler,et al.  Transferrin receptor is a marker of malignant phenotype in human pancreatic cancer and in neuroendocrine carcinoma of the pancreas. , 2004, European journal of cancer.

[110]  W. Pardridge,et al.  Intravenous RNA Interference Gene Therapy Targeting the Human Epidermal Growth Factor Receptor Prolongs Survival in Intracranial Brain Cancer , 2004, Clinical Cancer Research.

[111]  B. Jaber,et al.  Iron storage indices: novel predictors of bacteremia in hemodialysis patients initiating intravenous iron therapy. , 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[112]  R. Graf,et al.  Cerebral Ischemia and Reperfusion: The Pathophysiologic Concept as a Basis for Clinical Therapy , 2004, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[113]  W. Buurman,et al.  Reduction of circulating redox-active iron by apotransferrin protects against renal ischemia-reperfusion injury1 , 2004, Transplantation.

[114]  J. Wernly Ischemia, reperfusion, and the role of surgery in the treatment of cardiogenic shock secondary to acute myocardial infarction: an interpretative review. , 2004, The Journal of surgical research.

[115]  L. Lai,et al.  Pathogenesis of renal ischemia/reperfusion injury: lessons from knockout mice. , 2003, Life sciences.

[116]  C. Leisser,et al.  Transferrin ensures survival of ovarian carcinoma cells when apoptosis is induced by TNFα, FasL, TRAIL, or Myc , 2003, Oncogene.

[117]  Michael Weaver,et al.  Transferrin Receptor Ligand-Targeted Toxin Conjugate (Tf-CRM107) for Therapy of Malignant Gliomas , 2003, Journal of Neuro-Oncology.

[118]  Lei Shi,et al.  The inhibitory activity of serum to prevent bacterial adhesion is mainly due to apo-transferrin. , 2003, Journal of biomedical materials research. Part A.

[119]  T. Ruutu,et al.  Apotransferrin administration prevents growth of Staphylococcus epidermidis in serum of stem cell transplant patients by binding of free iron. , 2003, FEMS immunology and medical microbiology.

[120]  Corina I. García,et al.  Differential effects of apotransferrin on two populations of oligodendroglial cells , 2003, Glia.

[121]  M. Shoji,et al.  Targeting of post-ischemic cerebral endothelium in rat by liposomes bearing polyethylene glycol-coupled transferrin , 2003, Neurological research.

[122]  C. van Campenhout,et al.  Transferrin Modifications and Lipid Peroxidation: Implications in Diabetes Mellitus , 2003, Free radical research.

[123]  Hongzhe Sun,et al.  Targeted Drug Delivery via the Transferrin Receptor-Mediated Endocytosis Pathway , 2002, Pharmacological Reviews.

[124]  K. Kowdley,et al.  Haemochromatosis , 2002, Alimentary pharmacology & therapeutics.

[125]  K. Kamiński,et al.  Oxidative stress and neutrophil activation--the two keystones of ischemia/reperfusion injury. , 2002, International journal of cardiology.

[126]  J. Parkkinen,et al.  Function and Therapeutic Development of Apotransferrin , 2002, Vox sanguinis.

[127]  E. Wagner,et al.  Tumor-targeted gene delivery: an attractive strategy to use highly active effector molecules in cancer treatment , 2002, Gene Therapy.

[128]  S. Kane,et al.  Transferrin overcomes drug resistance to artemisinin in human small-cell lung carcinoma cells. , 2002, Cancer letters.

[129]  Z. Qian,et al.  Transferrin/transferrin receptor‐mediated drug delivery , 2002, Medicinal research reviews.

[130]  K. Maruyama,et al.  Intracellular targeting therapy of cisplatin‐encapsulated transferrin‐polyethylene glycol liposome on peritoneal dissemination of gastric cancer , 2002, International journal of cancer.

[131]  D. Richardson,et al.  The iron metabolism of neoplastic cells: alterations that facilitate proliferation? , 2002, Critical reviews in oncology/hematology.

[132]  P. Sadler,et al.  Unusual features for zirconium(IV) binding to human serum transferrin , 2002, JBIC Journal of Biological Inorganic Chemistry.

[133]  T. Momoi,et al.  Induction of bud formation of embryonic mouse tracheal epithelium by fibroblast growth factor plus transferrin in mesenchyme‐free culture , 2001, Developmental dynamics : an official publication of the American Association of Anatomists.

[134]  H. Deeg,et al.  Pro-apoptotic and anti-apoptotic effects of transferrin and transferrin-derived glycans on hematopoietic cells and lymphocytes. , 2001, Experimental hematology.

[135]  E. Beutler,et al.  Molecular characterization of a case of atransferrinemia. , 2000, Blood.

[136]  S. P. Vyas,et al.  Endogenous carriers and ligands in non-immunogenic site-specific drug delivery. , 2000, Advanced drug delivery reviews.

[137]  R. MacGillivray,et al.  The chloride effect is related to anion binding in determining the rate of iron release from the human transferrin N-lobe. , 2000, The Biochemical journal.

[138]  N. Andrews,et al.  The molecular defect in hypotransferrinemic mice. , 2000, Blood.

[139]  Hiroshi Kawabata,et al.  Transferrin Receptor 2-α Supports Cell Growth Both in Iron-chelated Cultured Cells and in Vivo * , 2000, The Journal of Biological Chemistry.

[140]  R. Elliott,et al.  Doxorubicin-gallium-transferrin conjugate overcomes multidrug resistance: evidence for drug accumulation in the nucleus of drug resistant MCF-7/ADR cells. , 2000, Anticancer research.

[141]  M. Hirose The Structural Mechanism for Iron Uptake and Release by Transferrins , 2000, Bioscience, biotechnology, and biochemistry.

[142]  P J Sadler,et al.  Transferrin as a metal ion mediator. , 1999, Chemical reviews.

[143]  H. Koeffler,et al.  Molecular Cloning of Transferrin Receptor 2 , 1999, The Journal of Biological Chemistry.

[144]  N. Ohkohchi,et al.  Kupffer's cells modulate neutrophile activity by superoxide anion and tumor necrosis factor-delta in reperfusion injury of liver transplantation-mechanisms of radical generation and reperfusion injury after cold ischemia. , 1999, Transplantation proceedings.

[145]  H. Baker,et al.  Two high-resolution crystal structures of the recombinant N-lobe of human transferrin reveal a structural change implicated in iron release. , 1998, Biochemistry.

[146]  E. Morgan,et al.  Transport mechanisms for iron and other transition metals in rat and rabbit erythroid cells , 1998, The Journal of physiology.

[147]  R. Micetich,et al.  Transferrin directed delivery of adriamycin to human cells. , 1998, Anticancer research.

[148]  D. Ribatti,et al.  Transferrin Promotes Endothelial Cell Migration and Invasion: Implication in Cartilage Neovascularization , 1997, The Journal of cell biology.

[149]  T. Okamoto,et al.  Effects of insulin and transferrin on the generation of lymphokine-activated killer cells in serum-free medium. , 1996, Journal of immunological methods.

[150]  K. Sakurai,et al.  Inhibition of microsomal lipid peroxidation by baicalein: A possible formation of an iron‐baicalein complex , 1996, Biochemistry and molecular biology international.

[151]  B. Lönnerdal,et al.  Lactoferrin: molecular structure and biological function. , 1995, Annual review of nutrition.

[152]  G. Nicolson,et al.  The role of trophic factors and autocrine/paracrine growth factors in brain metastasis , 1995, Clinical & Experimental Metastasis.

[153]  R. Cancedda,et al.  Ovotransferrin and ovotransferrin receptor expression during chondrogenesis and endochondral bone formation in developing chick embryo , 1994, The Journal of cell biology.

[154]  Y. Wada,et al.  Studies on familial hypotransferrinemia: unique clinical course and molecular pathology. , 1993, American journal of human genetics.

[155]  N. Brünner,et al.  Differences in transferrin response and numbers of transferrin receptors in rat and human mammary carcinoma lines of different metastatic potentials , 1993, Journal of cellular physiology.

[156]  B. Lönnerdal,et al.  Lactoferrin, lactoferrin receptors and iron metabolism. , 1993, European journal of clinical nutrition.

[157]  R. Pakala,et al.  Thyroid hormone dependent pituitary tumor cell growth in serum-free chemically defined culture. A new regulatory role for apotransferrin. , 1991, Biochemistry.

[158]  R. Starzyk,et al.  Anti-transferrin receptor antibody and antibody-drug conjugates cross the blood-brain barrier. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[159]  R. Weissleder,et al.  Receptor imaging: application to MR imaging of liver cancer. , 1990, Radiology.

[160]  M. Skinner,et al.  Transferrin gene expression and synthesis by cultured choroid plexus epithelial cells. Regulation by serotonin and cyclic adenosine 3',5'-monophosphate. , 1989, The Journal of biological chemistry.

[161]  M. Grisham,et al.  A role for iron in oxidant-mediated ischemic injury to intestinal microvasculature. , 1987, The American journal of physiology.

[162]  C. Finch,et al.  The physiology of transferrin and transferrin receptors. , 1987, Physiological reviews.

[163]  E. Ozawa,et al.  Class specificity of transferrin as a muscle trophic factor , 1986, Journal of cellular physiology.

[164]  W. Dreyer,et al.  Primary structure of the human melanoma-associated antigen p97 (melanotransferrin) deduced from the mRNA sequence. , 1986, Proceedings of the National Academy of Sciences of the United States of America.

[165]  B. Bloch,et al.  Transferrin gene expression visualized in oligodendrocytes of the rat brain by using in situ hybridization and immunohistochemistry. , 1985, Proceedings of the National Academy of Sciences of the United States of America.

[166]  F. Schoentgen,et al.  Human lactotransferrin: amino acid sequence and structural comparisons with other transferrins. , 1984, European journal of biochemistry.

[167]  B. Iacopetta,et al.  Intravesicular pH and iron uptake by immature erythroid cells , 1984, Journal of cellular physiology.

[168]  C. Hopkins,et al.  Internalization and processing of transferrin and the transferrin receptor in human carcinoma A431 cells , 1983, The Journal of cell biology.

[169]  A. Ciechanover,et al.  pH and the recycling of transferrin during receptor-mediated endocytosis. , 1983, Proceedings of the National Academy of Sciences of the United States of America.

[170]  T. Elleman,et al.  The primary structure of hen ovotransferrin. , 1982, European journal of biochemistry.

[171]  I. Trowbridge,et al.  Anti-transferrin receptor monoclonal antibody and toxin–antibody conjugates affect growth of human tumour cells , 1981, Nature.

[172]  P. Aisen,et al.  Distribution of iron between the binding sites of transferrin in serum: methods and results in normal human subjects. , 1979, Blood.

[173]  E. Morgan,et al.  The kinetics of the interaction between rabbit transferrin and reticulocytes. , 1969, Biochemistry.

[174]  H. S. Gutowsky,et al.  NUCLEAR MAGNETIC RESONANCE , 1954 .

[175]  A. L. Schade,et al.  An Iron-binding Component in Human Blood Plasma. , 1946, Science.

[176]  A. Stack,et al.  Transferrin Saturation: A Body Iron Biomarker. , 2016, Advances in clinical chemistry.

[177]  Jonathan D. Ashley,et al.  Ligand-targeted liposome design: challenges and fundamental considerations. , 2014, Trends in biotechnology.

[178]  Ying Zhang,et al.  Advanced materials and processing for drug delivery: the past and the future. , 2013, Advanced drug delivery reviews.

[179]  C. Baines,et al.  Cell biology of ischemia/reperfusion injury. , 2012, International review of cell and molecular biology.

[180]  N. Sibson,et al.  Detection of brain pathology by magnetic resonance imaging of iron oxide micro-particles. , 2011, Methods in molecular biology.

[181]  R. Choudhury,et al.  Chapter 4 - Applications of nanotechnology in molecular imaging of the brain. , 2009, Progress in brain research.

[182]  Sanjay K. Jain,et al.  PEGylation: an approach for drug delivery. A review. , 2008, Critical reviews in therapeutic drug carrier systems.

[183]  K. Zirvi Development of serum-free media for the growth of human gastrointestinal adenocarcinoma xenografts as primary tissue cultures , 2005, Journal of Cancer Research and Clinical Oncology.

[184]  Ernest Beutler,et al.  Iron deficiency and overload. , 2003, Hematology. American Society of Hematology. Education Program.

[185]  S. Vyas,et al.  Ligand-receptor-mediated drug delivery: an emerging paradigm in cellular drug targeting. , 2001, Critical reviews in therapeutic drug carrier systems.

[186]  R. Elliott,et al.  Antineoplastic drugs that interfere with iron metabolism in cancer cells. , 1997, Advances in enzyme regulation.

[187]  L. Yeoman,et al.  Transferrin and insulin enhance human colon tumor cell growth by differentiation class specific mechanisms. , 1996, Oncology research.

[188]  S. E. Bernstein Hereditary hypotransferrinemia with hemosiderosis, a murine disorder resembling human atransferrinemia. , 1987, The Journal of laboratory and clinical medicine.

[189]  P. Cohen,et al.  The Journal of Clinical Endocrinology & Metabolism Printed in U.S.A. Copyright © 2001 by The Endocrine Society Transferrin Is an Insulin-Like Growth Factor-Binding Protein-3 Binding Protein* , 2022 .